The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1559
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
The full article is available to subscribers Subscriber Login   

The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in adults. Fremanezumab and galcanezumab are the second and third subcutaneously injected monoclonal antibodies that target the CGRP pathway to be approved by the FDA for this indication; erenumab-aooe (Aimovig), which targets the CGRP receptor, was the first.1

MIGRAINE PREVENTION — Patients with frequent or severe migraine headaches and those who cannot take or do not have an adequate response to acute treatment are candidates for preventive treatment.2,3

Beta blockers and the antiepileptic drugs valproate (Depakote, and others) and topiramate (Topamax, and generics) are commonly used for ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
Article code: 1559a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian